Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insys Therapeutics, a developer of pharmaceutical products, has filed new drug application (NDA) for its cancer pain product candidate, Fentanyl SL Spray with the US Food and Drug Administration.
Subscribe to our email newsletter
Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products.
Insys CEO Michael Babich said this is a tremendous achievement for the company, and evidences their continued dedication to the development of improved products in the supportive care and oncology space.
"We are excited for the prospects of Fentanyl SL Spray’s unique delivery system and look forward to building a sales force to launch this product candidate, if approved," Babich said.